A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic

Dementia and Geriatric Cognitive Disorders

Volumn 30, Issue 4, 2010, Pages 285-292

  Morinaga, Akiyoshi ^a,b   Ono, Kenjiro ^a   Ikeda, Tokuhei ^a   Ikeda, Yoshihisa ^a   Shima, Keisuke ^a   Noguchi Shinohara, Moeko ^a,c   Samuraki, Miharu ^a,d   Yanase, Daisuke ^a   Yoshita, Mitsuhiro ^a   Iwasa, Kazuo ^a   Mastunari, Ichiro ^e   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b National Hospital Organization Iou National Hospital   (Japan)

^c ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d Keiju Medical Center   (Japan)

^e Medical and Pharmacological Research Center Foundation   (Japan)

Author keywords

Alzheimer's disease; Amyloid protein 1 42; CBF SPECT; CSF biomarkers; FDG PET; MRI; Phosphorylated tau; Total tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CYSTEINE ETHYL ESTER TC 99M; FLUORODEOXYGLUCOSE; PROTEIN TAUP; TAU PROTEIN; TAURINE TRANSPORTER; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN BLOOD FLOW; CEREBROSPINAL FLUID; CINGULATE GYRUS; DEMENTIA; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; METABOLIC RATE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID; EARLY DIAGNOSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TAU PROTEINS; TEMPORAL LOBE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77956803451     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320265     Document Type: Article

References (40)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
2. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC: Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143-1153.
3. Kesslak JP, Nalcioglu O, Cotman CW: Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology 1991; 41: 51-54.
4. Kogure D, Matsuda H, Ohnishi T, Asada T, Uno M, Kunihiro T, Nakano S, Takasaki M: Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med 2000; 41: 1155-1162. (Pubitemid 30463997)
5. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE: A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine- 18-FDG PET. J Nucl Med 1995; 36: 1238-1248.
6. O'Brien JT: Role of imaging techniques in the diagnosis of dementia. Br J Radiol 2007; 80:S71-S75.
7. Blennow K, Hampel H: CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-613. (Pubitemid 37162569)
8. Klunk WE, Engler H, Nordberg A, Wang Y, Biomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319. (Pubitemid 38269583)
9. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, Kemppainen N, Någren K, Kim BC, Tsui W, de Leon MJ: Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2008; 35: 2169-2181.
10. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA: Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009; 66: 1469-1475.
11. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L: Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 2005; 1: 55-66. (Pubitemid 43348857)
12. Chupin M, Gérardin E, Cuingnet R, Boutet C, Lemieux L, Lehéricy S, Benali H, Garnero L, Colliot O; Alzheimer's Disease Neuroimaging Initiative: Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI. Hippocampus 2009; 19: 579-587.
13. Evans MC, Barnes J, Nielsen C, Kim LG, Clegg SL, Blair M, Leung KK, Douiri A, Boyes RG, Ourselin S, Fox NC; Alzheimer's Disease Neuroimaging Initiative: Volume changes in Alzheimer's disease and mild cognitive impairment: Cognitive associations. Eur Radiol 2010; 20: 647-682.
14. Langbaum JB, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, Alexander GE, Foster NL, Weiner MW, Koeppe RA, Jagust WJ, Reiman EM; Alzheimer's Disease Neuroimaging Initiative: Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 2009; 45: 1107-1116.
15. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative: Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2009, Epub ahead of print.
16. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413.
17. Chou YY, Leporé N, Avedissian C, Madsen SK, Parikshak N, Hua X, Shaw LM, Trojanowski JQ, Weiner MW, Toga AW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative: Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage 2009; 46: 394-410.
18. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer's Disease Neuroimaging Initiative: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-1365.
19. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, Steinling M, Valk J: A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993; 114: 7-12. (Pubitemid 23025201)
20. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J: Atrophy of medial temporal lobes on MRI in 'probable' Alzheimer's disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55: 967-972.
21. Vermersch P, Leys D, Scheltens P, Barkhof F: Visual rating of hippocampal atrophy: Correlation with volumetry. J Neurol Neurosurg Psychiatry 1994; 57: 1015. (Pubitemid 24251084)
22. Matsuda H, Mizumura S, Soma T, Takemura N: Conversion of brain SPECT images between different collimators and reconstruction processes for analysis using statistical parametric mapping. Nucl Med Commun 2004; 25: 67-74. (Pubitemid 38183953)
23. Uchida Y, Minoshima S, Okada S, Kawata T, Ito H: Diagnosis of dementia using perfusion SPECT imaging at the patient's visit to a cognitive disorder clinic. Clin Nucl Med 2006; 31: 764-773. (Pubitemid 44789555)
24. Yanase D, Matsunari I, Yajima K, Chen W, Fujikawa A, Nishimura S, Matsuda H, Yamada M: Brain FDG PET study of normal aging in Japanese: Effect of atrophy correction. Eur J Nucl Med Mol Imaging 2005; 32: 794-805. (Pubitemid 41125422)
25. Chen WP, Samuraki M, Yanase D, Shima K, Takeda N, Ono K, Yoshita M, Nishimura S, Yamada M, Matsunari I: Effect of sample size for normal database on diagnostic performance of brain FDG PET for the detection of Alzheimer's disease using automated image analysis. Nucl Med Commun 2008; 29: 270-276. (Pubitemid 351499304)
26. Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, Ackermann U, Saunder T, Tochon-Danguy H, Jones G, Smith C, O'Keefe G, Masters CL, Rowe CC: Visual assessment versus quantitative assessment of 11 C-PIB PET and 18 F-FDG PET for detection of Alzheimer's disease. J Nucl Med 2007; 48: 547-552. (Pubitemid 47571408)
27. Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, Yamada M: Decreased-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2005; 237: 61-65. (Pubitemid 41384015)
28. Karas GB, Scheltens P, Rombouts SA, Visser PJ, van Schijndel RA, Fox NC, Barkhof F: Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage 2004; 23: 708-716. (Pubitemid 39370621)
29. Dougall NJ, Bruggink S, Enmeier KP: Systemic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 2004; 12: 554-570. (Pubitemid 41031058)
30. Patwardhan MB, McCrory DC, Matchar DB, Samsa GP, Rutschmann OT: Alzheimer disease: Operating characteristics of PET - a meta-analysis. Radiology 2004; 231: 73-80. (Pubitemid 38375412)
31. Nihashi T, Yatsuya H, Hayasaka K, Kato R, Kawatsu S, Arahata Y, Iwai K, Takeda A, Washimi Y, Yoshimura K, Mizuno K, Kato T, Naganawa S, Ito K: Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients. Radiat Med 2007; 25: 255-262. (Pubitemid 351928035)
32. Jensen M, Schröder J, Blomberg M, Engvall B, Pantel J, Ida N, Basun H, Wahlund LO, Werle E, Jauss M, Beyreuther K, Lannfelt L, Hartmann T: Cerebrospinal fluid A 42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 1999; 45: 504-511. (Pubitemid 29165817)
33. Samuels SC, Silverman JM, Marin DB, Peskind ER, Younki SG, Greenberg DA, Schnur E, Santoro J, Davis KL: CSF ß-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology 1999; 52: 547-551. (Pubitemid 29075601)
34. Tato RE, Frank A, Hernanz A: Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1995; 59: 280-283.
35. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M: Longitudinal study of cerebrospinal fluid levels of tau, Aß1-40, and Aß1-42(43) in Alzheimer's disease: A study in Japan. Ann Neurol 1998; 44: 17-26. (Pubitemid 28323651)
36. Wallin AK, Blennow K, Andreasen N, Minthon L: CSF biomarkers for Alzheimer's Disease: Levels ofß-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 2006; 21: 131-138. (Pubitemid 43201321)
37. Ravaglia S, Bini P, Sinforiani E, Franciotta D, Zardini E, Tosca P, Moglia A, Costa A: Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia. Neurol Sci 2008; 29: 417-423.
38. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative: MRI and CSF biomarkers in normal, MCI, and AD subjects: Diagnostic discrimination and cognitive correlations. Neurology 2009; 73: 287-293.
39. Haense C, Buerger K, Kalbe E, Drzezga A, Teipel SJ, Markiewicz P, Herholz K, Heiss WD, Hampel H: CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease. Eur J Neurol 2008; 15: 1155-1162.
40. Kawachi T, Ishii K, Sakamoto S, Sasaki M, Mori T, Yamashita F, Matsuda H, Mori E: Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease. Eur J Nucl Med Mol Imaging 2006; 33: 801-809. (Pubitemid 43979688)